Michelle Xia

georgetown university

H指数:13

被引数:1,090

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence study

年轻耐力跑者中的高级别腺瘤：一项前瞻性假设生成流行病学研究

Cancer Epidemiology

IF2.3

2026-08-013

Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study

Anti-PD-1抗体penpulimab联合化疗治疗复发或转移性鼻咽癌: 一项随机双盲3期研究

Signal Transduction and Targeted Therapy

IF52.7

2026-04-080

OAAI

Shuang Huang; Feng Liu; Song Qu; Lisha Chen; Ping Zhou; Shenhong Qu; Xiaohong Ai; Yong Chen; Meilian Liu; Rensheng Wang; Kelvin KW Chan; Peng Zhang; Chunhong Hu; Jiyu Wen; Jian Zhang; Qin Lin; Xiaojiang Li; Kangsheng Gu; Li Xiang; Dongxia Wang; Jingao Li; Daren Lin; Desheng Hu; Jianwu Ding; Siyang Wang; Xiaoming Huang; Lin Wang; Feng Jin; David G. Pfister; Milena Perez Mak; Pedro Rafael Martins de Marchi; Yi Jiang; Haihua Yang; Xiaoye Hu; Tianrun Liu; Dehua Wu; Aditya Shreenivas; Thiago Bueno de Oliveira; Carlos Eduardo Baston Silva; Gustavo Vasconcelos Alves; Xianming Li; Zhifang Yao; Dongmei Lu; Mingxiu Hu; Zhongmin Maxwell Wang; Baiyong Li; Michelle Xia; Xiaozhong Chen; Chaosu Hu; Tingting Xu

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

Ivonescimab 联合化疗与 tislelizumab 联合化疗作为晚期鳞状非小细胞肺癌的一线治疗（HARMONi-6）：一项随机、双盲、Ⅲ期临床试验

The Lancet

IF97.3

2025-10-190

PRE

Zhiwei Chen; Fang Yang; Zhou Jiang; Longhua Sun; Lin Wu; Zhengxiang Han; Yun Fan; Yanqiu Zhao; Xingya Li; Haipeng Xu; Xiangjiao Meng; Ying Liu; Zhiye Zhang; Hui Luo; Xuelei Ma; Xuezhen Ma; Qin Shi; Zhongmin Zhang; Runxiang Yang; Pingli Wang; Pinhua Pan; Xiaohong Ai; Jie Li; Xingxiang Pu; Zhiwu Wang; Jian Fang; Ming He; Yong He; Shuliang Guo; Juan Li; Hongbiao Wang; Junqiang Zhang; Qian Chu; Xuewen Liu; Shenpeng Ying; Hongcheng Wu; Hongmei Sun; Yinghua Ji; Ming Zhou; Chao Cao; Kejing Tang; Zhengguo Li; Dairong Li; Zhihong Zhang; Jie Li; Jianya Zhou; Hongzhong Yang; Yingying Du; Hui Yang; Jian Shi; Hualin Chen; Wenting Li; Dongmei Lu; Mingxiu Hu; Zhongmin Maxwell Wang; Baiyong Li; Michelle Xia; Shun Lu

Enhancing Multivariate Claim Regression with Gaussian Mixture Copula Clustering

North American Actuarial Journal

IF1.6

2025-10-010

PRE

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

卡多尼单抗联合铂类化疗加或不加贝伐单抗作为一线治疗持续性、复发性或转移性宫颈癌 (COMPASSION-16): 一项随机、双盲、安慰剂对照的中国3期临床试验

LANCET

IF88.5

2024-10-011

PRE

Wu, Xiaohua; Sun, Yang; Yang, Hongying; Wang, Jing; Lou, Hanmei; Li, Dan; Wang, Ke; Zhang, Hui; Wu, Tao; Li, Yuzhi; Wang, Chunyan; Li, Guiling; Wang, Yifeng; Li, Dapeng; Tang, Ying; Pan, Mei; Cai, Hongyi; Wang, Weihu; Yang, Bing; Qian, Hua; Tian, Qiuhong; Yao, Desheng; Cheng, Ying; Wei, Bing; Li, Xiumin; Wang, Tao; Hao, Min; Wang, Xiaohong; Wang, Tiejun; Ran, Juntao; Zhu, Hong; Zhu, Lijing; Liu, Xianling; Li, Yunxia; Chen, Lihong; Li, Qingshan; Yan, Xiaojian; Wang, Fei; Cai, Hongbing; Zhang, Yunyan; Liang, Zhiqing; Liu, Funan; Huang, Yi; Xia, Bairong; Qu, Pengpeng; Zhu, Genhai; Chen, Youguo; Song, Kun; Sun, Meili; Chen, Zhengzheng; Zhou, Qiang; Hu, Lina; Abulizi, Guzhalinuer; Guo, Hongyan; Liao, Sihai; Ye, Yijing; Yan, Ping; Tang, Qiu; Sun, Guoping; Liu, Ting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin M.; Li, Baiyong; Xia, Michelle

Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab

PHARMACOLOGICAL RESEARCH

IF10.5

2024-09-013

OAAI

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial

Ivonescimab联合化疗治疗EGFR变异的非小细胞肺癌随机临床试验

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2024-08-209

Fang, Wenfeng; Zhao, Yuanyuan; Luo, Yongzhong; Yang, Runxiang; Huang, Yan; He, Zhiyong; Zhao, Hui; Li, Mingjun; Li, Kai; Song, Qibing; Du, Xiaobo; Sun, Yulan; Li, Wei; Xu, Fei; Wang, Zhiyu; Yang, Kunning; Fan, Yun; Liu, Baogang; Zhao, Hongyun; Hu, Ying; Jia, Li; Xu, Shen; Yi, Tienan; Lv, Dongqing; Lan, Haitao; Li, Mengxia; Liang, Wenhua; Wang, Yongsheng; Yang, Hui; Jia, Yuming; Chen, Yuan; Lu, Junguo; Feng, Jifeng; Liu, Chunling; Zhou, Ming; Zhou, Jianya; Liu, Xianling; Zhou, Ningning; He, Ming; Dong, Xiaorong; Chen, Hualin; Chen, Yongxing; Su, Haichuan; Li, Xiaoling; Zhang, Zhihong; Yang, Lei; Cheng, Ying; Chen, Likun; Hou, Xue; Zhang, Yu; Guo, Jun; Wang, Zhen; Lu, Hong; Wu, Di; Feng, Weineng; Li, Wen; Huang, Jianan; Wang, Yan; Song, Xia; Peng, Jiewen; Liu, Laiyu; Guo, Yubiao; Li, Wenting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Zhang, Li

Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial

NATURE MEDICINE

IF50

2024-05-226

PRE

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-10-2417

OAAI

Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Ra Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study

DERMATOLOGY AND THERAPY